BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/1/2024 6:03:24 AM | Browse: 279 | Download: 685
 |
Received |
|
2024-04-07 13:21 |
|
Peer-Review Started |
|
2024-04-07 13:21 |
|
First Decision by Editorial Office Director |
|
2024-04-30 09:08 |
|
Return for Revision |
|
2024-04-30 09:08 |
|
Revised |
|
2024-05-23 14:47 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2024-06-03 02:44 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2024-06-03 10:00 |
|
Articles in Press |
|
2024-06-03 10:00 |
|
Edit the Manuscript by Language Editor |
|
2024-06-16 17:56 |
|
Typeset the Manuscript |
|
2024-06-27 08:29 |
|
Publish the Manuscript Online |
|
2024-07-01 06:03 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Case Report |
| Article Title |
Advanced lung adenocarcinoma with EGFR 19-del mutation transformed into squamous cell carcinoma after EGFR-tyrosine kinase inhibitors treatment: A case report
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Xing-Zu Ji, Zhong-Da Liu, Yi-Ping Ye, Quan Li, Xiao-Jing Liu, Min-Hua Zhou and Yi Jin |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Yi Jin, BMed, Attending Doctor, Department of Emergency Medicine, Lishui People's Hospital, No. 15 Mass Street, Liandu District, Lishui 323000, Zhejiang Province, China. 15990421805@163.com |
| Key Words |
Lung adenocarcinoma; Squamous cell carcinoma; Pathological histological transformation; Epidermal growth factor receptor tyrosine kinase inhibitor; Drug resistance; Case report |
| Core Tip |
Patients inevitably encounter drug resistance issues after receiving epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) treatment; EGFR-TKI resistance can be divided into primary and acquired. Pathological transformation is one of the mechanisms of acquired resistance in EGFR-TKIs, with squamous cell carcinoma transformation being relatively rare. This study provides detailed insights into a 67-year-old female patient with EGFR 19-del mutation in advanced lung adenocarcinoma who developed drug resistance after treatment with EGFR-TKIs. Our results provide a detailed analysis of the patient’s diagnosis and treatment process, alongside a review of literature on squamous cell carcinoma transformation after EGFR-TKI treatment for lung adenocarcinoma. |
| Publish Date |
2024-07-01 06:03 |
| Citation |
Ji XZ, Liu ZD, Ye YP, Li Q, Liu XJ, Zhou MH, Jin Y. Advanced lung adenocarcinoma with EGFR 19-del mutation transformed into squamous cell carcinoma after EGFR-tyrosine kinase inhibitors treatment: A case report. World J Clin Cases 2024; 12(20): 4405-4411 |
| URL |
https://www.wjgnet.com/2307-8960/full/v12/i20/4405.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v12.i20.4405 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
